Sort:
Date
Filter:
All

84 result(s) found

Novartis Ag (NVS) Q2 2024 Earnings Call Transcript https://www.fool.com/earnings/call-transcripts/2024/07/18/novartis-ag-nvs-q2-2024-earnings-call-transcript/?source=iedfolrf0000001 Jul 18, 2024 - NVS earnings call for the period ending June 30, 2024.
Is Main Street Capital (MAIN) Stock Outpacing Its Finance Peers This Year? https://www.zacks.com/stock/news/2299950/is-main-street-capital-main-stock-outpacing-its-finance-peers-this-year?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_1-2299950 Jul 11, 2024 - Here is how Main Street Capital (MAIN) and Aegon NV (AEG) have performed compared to their sector so far this year.
FDA Accepts Ionis' (IONS) NDA for Rare Disease Drug Olezarsen https://www.zacks.com/stock/news/2293892/fda-accepts-ionis-ions-nda-for-rare-disease-drug-olezarsen?cid=CS-ZC-FT-analyst_blog|company_news_medical_sector-2293892 Jun 26, 2024 - The FDA grants priority review to Ionis' (IONS) filing seeking approval for olezarsen to treat adults with familial chylomicronemia syndrome. A final decision is expected in December 2024.
Ionis (IONS) Expands Licensing Deal With Otsuka for HAE Drug https://www.zacks.com/stock/news/2290616/ionis-ions-expands-licensing-deal-with-otsuka-for-hae-drug?cid=CS-ZC-FT-analyst_blog|company_news_medical_sector-2290616 Jun 19, 2024 - Ionis (IONS) out-licenses the rights for its HAE drug to Otsuka in the Asia-Pacific region. The companies signed a similar deal last year granting Otsuka rights to market the drug in Europe.
Why Novartis (NVS) is a Top Value Stock for the Long-Term https://www.zacks.com/stock/news/2284645/why-novartis-nvs-is-a-top-value-stock-for-the-long-term?cid=CS-ZC-FT-tale_of_the_tape|zacks_education_value_score-2284645 Jun 06, 2024 - Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Why Novartis (NVS) is a Top Momentum Stock for the Long-Term https://www.zacks.com/stock/news/2283315/why-novartis-nvs-is-a-top-momentum-stock-for-the-long-term?cid=CS-ZC-FT-tale_of_the_tape|zacks_education_momentum_score-2283315 Jun 04, 2024 - Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Is ASM International (ASMIY) Stock Outpacing Its Computer and Technology Peers This Year? https://www.zacks.com/stock/news/2283248/is-asm-international-asmiy-stock-outpacing-its-computer-and-technology-peers-this-year?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_1-2283248 Jun 04, 2024 - Here is how ASM International NV (ASMIY) and Celestica (CLS) have performed compared to their sector so far this year.
Novartis AG (NVS) Investor Event at ASCO Conference Call (Transcript) https://seekingalpha.com/article/4697234-novartis-ag-nvs-investor-event-asco-conference-call-transcript?source=feed_sector_transcripts Jun 03, 2024 -
Novartis (NVS) Reports Positive Long-Term Data on CSU Drug https://www.zacks.com/stock/news/2282326/novartis-nvs-reports-positive-long-term-data-on-csu-drug?cid=CS-ZC-FT-analyst_blog|company_news_medical_sector-2282326 May 31, 2024 - Novartis (NVS) reports phase III data that confirm sustained efficacy and long-term safety of oral remibrutinib in chronic spontaneous urticaria.
Novartis reports positive Phase 3 data for remibrutinib for chronic hives https://seekingalpha.com/news/4111993-novartis-reports-positive-phase-3-data-for-remibrutinib-for-chronic-hives?source=feed_sector_healthcare May 31, 2024 - Novartis (NVS) reported positive Phase 3 data for its autoimmune drug remibrutinib in the treatment of chronic spontaneous urticaria, or hives. Read more here.

Pages: 123456789

<<<Page 3>